{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:58:27Z","timestamp":1778738307766,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Oral Invest"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00784-018-2720-7","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T22:49:38Z","timestamp":1540507778000},"page":"2743-2750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy of ultramicronized palmitoylethanolamide in burning mouth syndrome-affected patients: a preliminary randomized double-blind controlled trial"],"prefix":"10.1007","volume":"23","author":[{"given":"Giulia","family":"Ottaviani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Rupel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Gobbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusto","family":"Poropat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Zoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Faraon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Di Lenarda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-6115","authenticated-orcid":false,"given":"Matteo","family":"Biasotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"key":"2720_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3748\/wjg.v19.i5.665","volume":"19","author":"GE Gurvits","year":"2013","unstructured":"Gurvits GE, Tan A (2013) Burning mouth syndrome. World J Gastroenterol 19:665\u2013672","journal-title":"World J Gastroenterol"},{"key":"2720_CR2","first-page":"213","volume":"8","author":"C Salerno","year":"2016","unstructured":"Salerno C, Di Stasio D, Petruzzi M, Lauritano D, Gentile E, Guida A, Maio C, Tammaro M, Serpico R, Lucchese A (2016) An overview of burning mouth syndrome. Front Biosci (Elite Ed) 1 8:213\u2013218","journal-title":"Front Biosci (Elite Ed) 1"},{"key":"2720_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/qjmed\/hcm049","volume":"100","author":"S Fedele","year":"2007","unstructured":"Fedele S, Fricchione G, Porter SR, Mignogna MD (2007) Burning mouth syndrome (stomatodynia). QJM 100:527\u2013530","journal-title":"QJM"},{"issue":"2","key":"2720_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5005\/jp-journals-10024-1822","volume":"17","author":"S Vellappally","year":"2016","unstructured":"Vellappally S (2016) Burning mouth syndrome: a review of the etiopathologic factors and management. J Contemp Dent Pract 17(2):171\u2013176","journal-title":"J Contemp Dent Pract"},{"key":"2720_CR5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.pain.2005.03.028","volume":"115","author":"G Lauria","year":"2005","unstructured":"Lauria G, Majorana A, Borgna M, Lombardi R, Penza P, Padovani A, Sapelli P (2005) Trigeminal small-fiber sensory neuropathy causes burning mouth syndrome. Pain 115:332\u2013337","journal-title":"Pain"},{"key":"2720_CR6","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.jocn.2006.09.002","volume":"14","author":"Z Yilmaz","year":"2007","unstructured":"Yilmaz Z, Renton T, Yiangou Y, Zakrzewska J, Chessell IP, Bountra C, Anand P (2007) Burning mouth syndrome as a trigeminal small fibre neuropathy: increased heat and capsaicin receptor TRPV1 in nerve fibres correlates with pain score. J Clin Neurosci 14:864\u2013871","journal-title":"J Clin Neurosci"},{"issue":"4","key":"2720_CR7","first-page":"523","volume":"29","author":"E Borsani","year":"2014","unstructured":"Borsani E, Majorana A, Cocchi MA, Conti G, Bonadeo S, Padovani A, Lauria G, Bardellini E, Rezzani R, Rodella LF (2014) Epithelial expression of vanilloid and cannabinoid receptors: a potential role in burning mouth syndrome pathogenesis. Histol Histopathol 29(4):523\u2013533","journal-title":"Histol Histopathol"},{"issue":"4","key":"2720_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/jop.12692","volume":"47","author":"A Barry","year":"2018","unstructured":"Barry A, O'Halloran KD, McKenna JP, McCreary C, Harhen B, Kerr DM, Finn DP, Downer EJ (2018) Plasma N-acylethanolamine and endocannabinoid levels in burning mouth syndrome: potential role in disease pathogenesis. J Oral Pathol Med 47(4):440\u2013442","journal-title":"J Oral Pathol Med"},{"key":"2720_CR9","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ijom.2010.03.013","volume":"39","author":"K Beneng","year":"2010","unstructured":"Beneng K, Yilmaz Z, Yiangou Y, McParland H, Anand P, Renton T (2010) Sensory purinergic receptor P2X3 is elevated in burning mouth syndrome. Int J Oral Maxillofac Surg 39:815\u2013819","journal-title":"Int J Oral Maxillofac Surg"},{"key":"2720_CR10","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.bbalip.2010.08.010","volume":"1801","author":"N Ueda","year":"2010","unstructured":"Ueda N, Tsuboi K, Uyama T (2010) Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim Biophys Acta 1801:1274\u20131285","journal-title":"Biochim Biophys Acta"},{"key":"2720_CR11","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/0006-291X(79)91281-6","volume":"90","author":"DE Epps","year":"1979","unstructured":"Epps DE, Schmid PC, Natarajan V, Schmid HH (1979) N-Acylethanolamine accumulation in infarcted myocardium. Biochem Biophys Res Commun 90:628\u2013633","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"2720_CR12","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/bph.13580","volume":"174","author":"S Petrosino","year":"2017","unstructured":"Petrosino S, Di Marzo V (2017) The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol 174(11):1349\u20131365","journal-title":"Br J Pharmacol"},{"key":"2720_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.pain.2008.06.003","volume":"139","author":"B Costa","year":"2008","unstructured":"Costa B, Comelli F, Bettoni I, Giagoni G (2008) The endogenous fatty acid amide, palmitoylethanolamide, reduces neuropathic pain after systemic administration in mice: involvement of CB1, TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 139:541\u2013550","journal-title":"Pain"},{"key":"2720_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/1871527311312010008","volume":"12","author":"I Bettoni","year":"2013","unstructured":"Bettoni I, Comelli F, Colombo A, Bonfanti P, Costa B (2013) Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. CNS Neurol Disord Drug Targets 12:34\u201344","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"2720_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2174\/1871527311312010009","volume":"12","author":"L Luongo","year":"2013","unstructured":"Luongo L, Guida F, Boccella S, Bellini G, Gatta L, Rossi F, de Novellis V, Maione S (2013) Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal gial\/microglial phenotypical changes in mice. CNS Neurol Disord Drug Targets 12:45\u201354","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"2720_CR16","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/j.1526-4637.2012.01432.x","volume":"13","author":"A Gatti","year":"2012","unstructured":"Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF (2012) Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogeneses. Pain Med 13:1121\u20131130","journal-title":"Pain Med"},{"key":"2720_CR17","first-page":"849623","volume":"2014","author":"C Schifilliti","year":"2014","unstructured":"Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C (2014) Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat 2014:849623","journal-title":"Pain Res Treat"},{"key":"2720_CR18","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/j.1526-4637.2010.00823.x","volume":"11","author":"RS Calabr\u00f2","year":"2010","unstructured":"Calabr\u00f2 RS, Gervasi G, Marino S, Mondo PN, Bramanti P (2010) Misdiagnosed chronic pelvic pain: pudendal neuralgia responding to a novel use of palmitoylethanolamide. Pain Med 11:781\u2013784","journal-title":"Pain Med"},{"key":"2720_CR19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.36076\/ppj\/2016.19.11","volume":"19","author":"A Paladini","year":"2016","unstructured":"Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G (2016) Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician 19:11\u201324","journal-title":"Pain Physician"},{"key":"2720_CR20","first-page":"c83","volume":"78","author":"GD Klasser","year":"2012","unstructured":"Klasser GD, Gremillion HA (2012) Neuropathic orofacial pain patients in need of dental care. J Can Dent Assoc 78:c83","journal-title":"J Can Dent Assoc"},{"key":"2720_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.biocel.2014.08.007","volume":"55","author":"P McDonough","year":"2014","unstructured":"McDonough P, McKenna JP, McCreary C, Downer EJ (2014) Neuropathic orofacial pain: cannabinoids as a therapeutic avenue. Int J Biochem Cell Biol 55:72\u201378. https:\/\/doi.org\/10.1016\/j.biocel.2014.08.007","journal-title":"Int J Biochem Cell Biol"},{"issue":"2","key":"2720_CR22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/jop.12666","volume":"47","author":"A Barry","year":"2018","unstructured":"Barry A, O'Halloran KD, McKenna JP, McCreary C, Downer EJ (2018) Plasma IL-8 signature correlates with pain and depressive symptomatology in patients with burning mouth syndrome: results from a pilot study. J Oral Pathol Med 47(2):158\u2013165","journal-title":"J Oral Pathol Med"},{"key":"2720_CR23","unstructured":"(2016) The International Classification of Headache Disorders, 3rd edition. International Headache Society"},{"key":"2720_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/sj.bdj.4806969","volume":"167","author":"PJ Lamey","year":"1989","unstructured":"Lamey PJ, Lewis MA (1989) Oral medicine in practice: burning mouth syndrome. Br Dent J 167:197\u2013200","journal-title":"Br Dent J"},{"issue":"6","key":"2720_CR25","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00520-008-0521-2","volume":"17","author":"N Ahmed","year":"2009","unstructured":"Ahmed N, Bestall J, Payne S, Noble B, Ahmedzai S (2009) The use of cognitive interviewing methodology in the design and testing of a screening tool for supportive and palliative care needs. Support Care Cancer 17(6):665\u2013673","journal-title":"Support Care Cancer"},{"key":"2720_CR26","doi-asserted-by":"crossref","unstructured":"Patton LL, Siegel MA, Benoliel R, De Laat A (2007) Management of burning mouth syndrome: systematic review and management recommendations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103 Suppl:S39.e1\u201313","DOI":"10.1016\/j.tripleo.2006.11.009"},{"issue":"4","key":"2720_CR27","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/odi.12807","volume":"24","author":"D Adamo","year":"2018","unstructured":"Adamo D, Sardella A, Varoni E, Lajolo C, Biasotto M, Ottaviani G, Vescovi P, Simonazzi T, Pentenero M, Ardore M, Spadari F, Bombeccari G, Montebugnoli L, Gissi DB, Campisi G, Panzarella V, Carbone M, Valpreda L, Giuliani M, Aria M, Lo Muzio L, Mignogna MD (2018) The association between burning mouth syndrome and sleep disturbance: a case-control multicentre study. Oral Dis 24(4):638\u2013649. https:\/\/doi.org\/10.1111\/odi.12807 Epub 2018 Mar 13","journal-title":"Oral Dis"},{"key":"2720_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0304-3959(00)00409-7","volume":"90","author":"SK J\u00e4\u00e4skel\u00e4inen","year":"2001","unstructured":"J\u00e4\u00e4skel\u00e4inen SK, Rinne JO, Forssell H, Tenovuo O, Kaasinen V, Sonninen P, Bergman J (2001) Role of the dopaminergic system in chronic pain\u2014a fluorodopa PET study. Pain 90:257\u2013260","journal-title":"Pain"},{"key":"2720_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0304-3959(03)00275-6","volume":"106","author":"N Hagelberg","year":"2003","unstructured":"Hagelberg N, Forssell H, Aalto S, Rinne JO, Scheinin H, Taiminen T, N\u00e5gren K, Eskola O, J\u00e4\u00e4skel\u00e4inen SK (2003) Altered dopamine D2 receptor binding in atypical facial pain. Pain 106:43\u201348","journal-title":"Pain"},{"key":"2720_CR30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s11916-013-0336-9","volume":"17","author":"L Charleston","year":"2013","unstructured":"Charleston L (2013) Burning mouth syndrome: a review of recent literature. Curr Pain Headache Rep 17:336. https:\/\/doi.org\/10.1007\/s11916-013-0336-9","journal-title":"Curr Pain Headache Rep"},{"key":"2720_CR31","unstructured":"Buchanan JA, Zakrzewska JM (2010) Burning mouth syndrome. BMJ Clin Evid 19;2010"},{"key":"2720_CR32","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/archotol.130.6.786","volume":"130","author":"TL White","year":"2004","unstructured":"White TL, Kent PF, Kurtz DB, Emko P (2004) Effectiveness of gabapentin for treatment of burning mouth syndrome. Arch Otolaryngol Head Neck Surg 130:786\u2013788","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2720_CR33","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1111\/j.1468-1331.2006.01294.x","volume":"13","author":"SM Heckmann","year":"2006","unstructured":"Heckmann SM, Heckmann JG, Ungeth\u00fcm A, Hujoel P, Hummel T (2006) Gabapentin has little or no effect in the treatment of burning mouth syndrome\u2014results of an open-label pilot study. Eur J Neurol 13:e6\u2013e7","journal-title":"Eur J Neurol"},{"key":"2720_CR34","doi-asserted-by":"publisher","first-page":"e635","DOI":"10.4317\/medoral.16942","volume":"16","author":"E L\u00f3pez-D\u2019alessandro","year":"2011","unstructured":"L\u00f3pez-D\u2019alessandro E, Escovich L (2011) Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of burning mouth syndrome: a randomized, double-blind, placebo controlled trial. Med Oral Patol Oral Cir Bucal 16:e635\u2013e640","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"2720_CR35","first-page":"615","volume":"65","author":"M Grushka","year":"2002","unstructured":"Grushka M, Epstein JB, Gorsky M (2002) Burning mouth syndrome. Am Fam Physician 65:615\u2013620","journal-title":"Am Fam Physician"},{"key":"2720_CR36","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s12035-013-8487-6","volume":"48","author":"SD Skaper","year":"2013","unstructured":"Skaper SD, Facci L, Giusti P (2013) Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol Neurobiol 48:340\u2013352","journal-title":"Mol Neurobiol"},{"issue":"1607","key":"2720_CR37","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1098\/rstb.2011.0391","volume":"367","author":"SD Skaper","year":"2012","unstructured":"Skaper SD, Facci L (2012) Mast cell \u2013 glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. Philos Trans R Soc Lond Ser B Biol Sci 367(1607):3312\u20133325","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci"},{"issue":"1","key":"2720_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neuropharm.2007.05.015","volume":"54","author":"GG Muccioli","year":"2008","unstructured":"Muccioli GG, Stella N (2008) Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology 54(1):16\u201322","journal-title":"Neuropharmacology"},{"key":"2720_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1744-8069-7-3","volume":"7","author":"D Filippis De","year":"2011","unstructured":"De Filippis D, Luongo L, Cipriano M, Palazzo E, Cinelli MP, De Novellis V, Maione S, Iuvone T (2011) Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol Pain 7:3","journal-title":"Mol Pain"},{"key":"2720_CR40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.plipres.2016.02.002","volume":"62","author":"FA Iannotti","year":"2016","unstructured":"Iannotti FA, Di Marzo V, Petrosino S (2016) Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. Prog Lipid Res 62:107\u2013128. https:\/\/doi.org\/10.1016\/j.plipres.2016.02.002","journal-title":"Prog Lipid Res"},{"key":"2720_CR41","doi-asserted-by":"publisher","first-page":"328797","DOI":"10.1155\/2013\/328797","volume":"2013","author":"L Cesare Mannelli Di","year":"2013","unstructured":"Di Cesare Mannelli L, D'Agostino G, Pacini A, Russo R, Zanardelli M, Ghelardini C, Calignano A (2013) Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediat Inflamm 2013:328797. https:\/\/doi.org\/10.1155\/2013\/328797","journal-title":"Mediat Inflamm"},{"issue":"2","key":"2720_CR42","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10787-013-0191-7","volume":"22","author":"SD Skaper","year":"2014","unstructured":"Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, Giusti P (2014) Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology 22(2):79\u201394","journal-title":"Inflammopharmacology"},{"issue":"6","key":"2720_CR43","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1111\/bph.12029","volume":"168","author":"P Ambrosino","year":"2013","unstructured":"Ambrosino P, Soldovieri MV, Russo C, Taglialatela M (2013) Activation and desensitization of TRPV1 channels in sensory neurons by the PPAR\u03b1 agonist palmitoylethanolamide. Br J Pharmacol 168(6):1430\u20131444. https:\/\/doi.org\/10.1111\/bph.12029","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2720_CR44","first-page":"237","volume":"13","author":"E Esposito","year":"2013","unstructured":"Esposito E, Cuzzocrea S (2013) Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. Mini Rev Med Chem 13(2):237\u2013255","journal-title":"Mini Rev Med Chem"},{"issue":"18","key":"2720_CR45","doi-asserted-by":"publisher","first-page":"30197","DOI":"10.1016\/j.jpain.2018.05.008","volume":"S1526-5900","author":"N Stensson","year":"2018","unstructured":"Stensson N, Ghafouri N, Ernberg M, Mannerkorpi K, Kosek E, Gerdle B, Ghafouri B (2018) The relationship of endocannabinoidome lipid mediators with pain and psychological stress in women with fibromyalgia\u2014a case control study. J Pain pii S1526-5900(18):30197\u201330194. https:\/\/doi.org\/10.1016\/j.jpain.2018.05.008","journal-title":"J Pain pii"},{"key":"2720_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/odi.12192","volume":"20","author":"M Kuten-Shorrer","year":"2014","unstructured":"Kuten-Shorrer M, Kelley JM, Sonis ST, Treister NS (2014) Placebo effect in burning mouth syndrome: a systematic review. Oral Dis 20:1\u20136","journal-title":"Oral Dis"}],"container-title":["Clinical Oral Investigations"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-018-2720-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00784-018-2720-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-018-2720-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T17:41:27Z","timestamp":1662313287000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00784-018-2720-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,25]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["2720"],"URL":"https:\/\/doi.org\/10.1007\/s00784-018-2720-7","relation":{},"ISSN":["1432-6981","1436-3771"],"issn-type":[{"value":"1432-6981","type":"print"},{"value":"1436-3771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,25]]},"assertion":[{"value":"27 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the University\u2019s Ethic Committee of Trieste (registration number 405\/69\/2010).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}